The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 74-80

  Muratori, Luigi ^a   Longhi, Maria Serena ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; Regulatory; Th17 Cells; Tocilizumab; Tolerance; Ustekinumab

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CD4 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; DRUG MEGADOSE; EFFECTOR CELL; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER INJURY; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; TH17 CELL; UNSPECIFIED SIDE EFFECT;

AUTOIMMUNITY; REGULATORY; TH17 CELLS; TOCILIZUMAB; TOLERANCE; USTEKINUMAB;

AUTOANTIGENS; CELL PROLIFERATION; CYTOKINES; HEPATITIS, AUTOIMMUNE; HUMANS; INFLAMMATION MEDIATORS; LIVER; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84886242509     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.06.016     Document Type: Review

References (112)

1. Krawitt E.L. Autoimmune hepatitis. NEngl J Med 2006, 354:54-66.
2. Muratori P., Granito A., Quarneti C., Ferri S., Menichella R., Cassani F., et al. Autoimmune hepatitis in Italy: the Bologna experience. JHepatol 2009, 50:1210-1218.
3. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
4. Vergani D., Alvarez F., Bianchi F.B., Cancado E.L., Mackay I.R., Manns M.P., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. JHepatol 2004, 41:677-683.
5. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
6. Gregorio G.V., Portmann B., Reid F., Donaldson P.T., Doherty D.G., McCartney M., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
7. Granito A., Muratori P., Ferri S., Pappas G., Quarneti C., Lenzi M., et al. Diagnosis and therapy of autoimmune hepatitis. Mini Rev Med Chem 2009, 9:847-860.
8. van Gerven N.M., Verwer B.J., Witte B.I., van Hoek B., Coenraad M.J., van Erpecum K.J., et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. JHepatol 2013, 58:141-147.
9. Czaja A.J. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011, 17:3120-3140.
10. Czaja A.J. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets 2012.
11. Czaja A.J. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-I. Inflamm Allergy Drug Targets 2012.
12. Czaja A.J. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol 2012, 26:615-620.
13. Selvarajah V., Montano-Loza A.J., Czaja A.J. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012, 36:691-707.
14. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. JAutoimmun 2010, 34:7-14.
15. Vergani D., Mieli-Vergani G. Cutting edge issues in autoimmune hepatitis. Clin Rev Allergy Immunol 2012, 42:309-321.
16. Zhao L., Qiu de K., Ma X. Th17 cells: the emerging reciprocal partner of regulatory T cells in the liver. JDig Dis 2010, 11:126-133.
17. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
18. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
19. Klein L., Jovanovic K. Regulatory T cell lineage commitment in the thymus. Semin Immunol 2011, 23:401-409.
20. Lio C.W., Hsieh C.S. Becoming self-aware: the thymic education of regulatory T cells. Curr Opin Immunol 2011, 23:213-219.
21. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-1227.
22. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. JExp Med 2003, 198:1875-1886.
23. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
24. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
25. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
26. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
27. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
28. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007, 8:277-284.
29. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
30. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006, 103:6659-6664.
31. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990.
32. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
33. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5:e38.
34. Gavin M., Rudensky A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol 2003, 15:690-696.
35. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 2009, 106:1903-1908.
36. Polansky J.K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008, 38:1654-1663.
37. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
38. Chen C., Rowell E.A., Thomas R.M., Hancock W.W., Wells A.D. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. JBiol Chem 2006, 281:36828-36834.
39. Li B., Samanta A., Song X., Furuuchi K., Iacono K.T., Kennedy S., et al. FOXP3 ensembles in T-cell regulation. Immunol Rev 2006, 212:99-113.
40. Samanta A., Li B., Song X., Bembas K., Zhang G., Katsumata M., et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A 2008, 105:14023-14027.
41. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: thekey to a stable regulatory T-cell lineage?. Nat Rev Immunol 2009, 9:83-89.
42. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21:274-280.
43. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
44. Feuerer M., Hill J.A., Mathis D., Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009, 10:689-695.
45. Hori S. Developmental plasticity of Foxp3+ regulatory T cells. Curr Opin Immunol 2010, 22:575-582.
46. Hori S. Regulatory T cell plasticity: beyond the controversies. Trends Immunol 2011, 32:295-300.
47. da Silva Martins M., Piccirillo C.A. Functional stability of Foxp3+ regulatory T cells. Trends Mol Med 2012, 18:454-462.
48. Sakaguchi S., Vignali D.A., Rudensky A.Y., Niec R.E., Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013.
49. Longhi M.S., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. JHepatol 2004, 41:31-37.
50. Ferri S., Longhi M.S., De Molo C., Lalanne C., Muratori P., Granito A., et al. Amultifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010, 52:999-1007.
51. Longhi M.S., Ma Y., Mitry R.R., Bogdanos D.P., Heneghan M., Cheeseman P., et al. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. JAutoimmun 2005, 25:63-71.
52. Longhi M.S., Hussain M.J., Mitry R.R., Arora S.K., Mieli-Vergani G., Vergani D., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. JImmunol 2006, 176:4484-4491.
53. Longhi M.S., Mitry R.R., Samyn M., Scalori A., Hussain M.J., Quaglia A., et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009, 50:130-142.
54. Peiseler M., Sebode M., Franke B., Wortmann F., Schwinge D., Quaas A., et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. JHepatol 2012, 57:125-132.
55. Wang P., Longhi M.S., Mieli-Vergani G., Vergani D., Ma Y. Multiple defects of the immunoregulatory system contribute to the development of autoimmune hepatitis. Hepatology 2011, 54:910A.
56. Liberal R., Grant C.R., Mieli-Vergani G., Vergani D., Longhi M.S. Phenotypic and functional signature of CD4posCD25highCD127low regulatory T-cells in autoimmune hepatitis. JHepatol 2012, 56:S374.
57. Zingaretti C., Arigó M., Cardaci A., Moro M., Crosti M., Sinisi A., et al. Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics 2012.
58. Marwaha A.K., Leung N.J., McMurchy A.N., Levings M.K. TH17 cells in autoimmunity and immunodeficiency: protective or pathogenic?. Front Immunol 2012, 3:129.
59. Maddur M.S., Miossec P., Kaveri S.V., Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012, 181:8-18.
60. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol 2012, 33:505-512.
61. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009, 9:883-889.
62. Zhu J., Paul W.E. Heterogeneity and plasticity of T helper cells. Cell Res 2010, 20:4-12.
63. Wilke C.M., Bishop K., Fox D., Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol 2011, 32:603-611.
64. Kryczek I., Zhao E., Liu Y., Wang Y., Vatan L., Szeliga W., et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011, 3. 104ra100.
65. Geiger T.L., Tauro S. Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function. Hum Immunol 2012, 73:232-239.
66. Miyao T., Floess S., Setoguchi R., Luche H., Fehling H.J., Waldmann H., et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012, 36:262-275.
67. Tartar D.M., van Morlan A.M., Zaghouani H. T-regulatory/T-helper 17: promiscuous signals and fear of commitment. Immunotherapy 2009, 1:27-29.
68. Pillai M.R., Collison L.W., Wang X., Finkelstein D., Rehg J.E., Boyd K., et al. The plasticity of regulatory T cell function. JImmunol 2011, 187:4987-4997.
69. Hoechst B., Gamrekelashvili J., Manns M.P., Greten T.F., Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011, 117:6532-6541.
70. Locksley R.M. Nine lives: plasticity among T helper cell subsets. JExp Med 2009, 206:1643-1646.
71. Zhao L., Tang Y., You Z., Wang Q., Liang S., Han X., et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE 2011, 6:e18909.
72. Oo Y.H., Adams D.H. Regulatory T cells and autoimmune hepatitis: defective cells or a hostile environment?. JHepatol 2012, 57:6-8.
73. Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
74. Zachou K., Gatselis N., Papadamou G., Rigopoulou E.I., Dalekos G.N. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. JHepatol 2011, 55:636-646.
75. Hyams J.S., Ballow M., Leichtner A.M. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987, 93:890-893.
76. Sherman K.E., Narkewicz M., Pinto P.C. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. JHepatol 1994, 21:1040-1047.
77. Van Thiel D.H., Wright H., Carroll P., Abu-Elmagd K., Rodriguez-Rilo H., McMichael J., et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:771-776.
78. Burak K.W., Urbanski S.J., Swain M.G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. JHepatol 1998, 29:990-993.
79. Fernandes N.F., Redeker A.G., Vierling J.M., Villamil F.G., Fong T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
80. Alvarez F., Ciocca M., Canero-Velasco C., Ramonet M., de Davila M.T., Cuarterolo M., et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. JHepatol 1999, 30:222-227.
81. Marlaka J.R., Papadogiannakis N., Fischler B., Casswall T.H., Beijer E., Nemeth A. Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis. Acta Paediatr 2012, 101:993-999.
82. Tannous M.M., Cheng J., Muniyappa K., Farooq I., Bharara A., Kappus M., et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011, 34:405-407.
83. Larsen F.S., Vainer B., Eefsen M., Bjerring P.N., Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232-3236.
84. Chatur N., Ramji A., Bain V.G., Ma M.M., Marotta P.J., Ghent C.N., et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005, 25:723-727.
85. Aqel B.A., Machicao V., Rosser B., Satyanarayana R., Harnois D.M., Dickson R.C. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. JClin Gastroenterol 2004, 38:805-809.
86. Nakamura K., Yoneda M., Yokohama S., Tamori K., Sato Y., Aso K., et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. JGastroenterol Hepatol 1998, 13:490-495.
87. Pratt D.S., Flavin D.P., Kaplan M.M. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996, 110:271-274.
88. Yarze J.C., Herlihy K.H., Fritz H.P., Poulos A.M. Azathioprine and 6-mercaptopurine and autoimmune hepatitis. Gastroenterology 1996, 110(6):2027.
89. Sultan M.I., Biank V.F., Telega G.W. Successful treatment of autoimmune hepatitis with methotrexate. JPediatr Gastroenterol Nutr 2011, 52:492-494.
90. Venkataramani A., Jones M.B., Sorrell M.F. Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001, 96:3432-3434.
91. Radhakrishnan S., Cabrera R., Schenk E.L., Nava-Parada P., Bell M.P., Van Keulen V.P., et al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors invitro and invivo. JImmunol 2008, 181:3137-3147.
92. Elliott M., Benson J., Blank M., Brodmerkel C., Baker D., Sharples K.R., et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009, 1182:97-110.
93. Mitra A., Fallen R.S., Lima H.C. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2012.
94. Navarro-Millan I., Singh J.A., Curtis J.R. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012, 34:788-802.e3.
95. Mahamid M., Mader R., Safadi R. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol 2011, 3:39-43.
96. Drucker C., Gewiese J., Malchow S., Scheller J., Rose-John S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. JAutoimmun 2010, 34:29-37.
97. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:2499-2503.
98. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010, 40:1830-1835.
99. Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007, 114:1-8.
100. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
101. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEngl J Med 2011, 365:2055-2066.
102. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. NEngl J Med 2011, 365:2067-2077.
103. Arnson Y., Shoenfeld Y., Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009, 42:553-560.
104. Maddur M.S., Vani J., Hegde P., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells byintravenous immunoglobulin. JAllergy Clin Immunol 2011, 127:823-830.e1-7.
105. Maddur M.S., Sharma M., Hegde P., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. JClin Immunol 2012.
106. Ephrem A., Chamat S., Miquel C., Fisson S., Mouthon L., Caligiuri G., et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
107. Kessel A., Ammuri H., Peri R., Pavlotzky E.R., Blank M., Shoenfeld Y., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. JImmunol 2007, 179:5571-5575.
108. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008, 112:3303-3311.
109. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
110. Cousens L.P., Najafian N., Mingozzi F., Elyaman W., Mazer B., Moise L., et al. Invitro and invivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. JClin Immunol 2013, 33(Suppl.1):S43-S49.
111. Longhi M.S., Meda F., Wang P., Samyn M., Mieli-Vergani G., Vergani D., et al. Expansion and de novo generation of potentially therapeutic regulatory Tcells in patients with autoimmune hepatitis. Hepatology 2008, 47:581-591.
112. Longhi M.S., Hussain M.J., Kwok W.W., Mieli-Vergani G., Ma Y., Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011, 53:536-547.